Water-soluble bactericidal reparative composition
|
Application of 4-(pyrrolidine-1-yl)quinoline compounds for elimination of clinically latent microorganisms / 2520766 Invention relates to the field of organic chemistry and medicine and deals with novel 4-(pyrrolidine-1-yl)quinoline compounds, a method of their obtaining and application for treatment of bacterial or fungal infection. |
 Compositions and methods of treating nail diseases / 2519664Invention relates to the field of pharmaceutics, namely represents compositions for treating nail and nail bed diseases and methods of treating nail diseases. |
 Complex preparation for preventing and treating intestinal infections / 2519659In a complex preparation containing a carrier representing an enterosorbent; the enterosorbent is modified by immobilising high-disperse silver - nanosilver in a concentration of 0.01 - 1.0 wt % on its surface. The enterosorbent represents activated carbon, kaolin, bentonit, or enterodesum, or monocrystalline cellulose. A modifying silver-containing solution - a nanosilver source - is silver clusters in an aqueous solution. |
 Topical composition possessing anti-inflammatory, analgesic, antirheumatic and antibacterial activity and method for preparing it / 2519330Group of inventions refers to medicine and concerns a local topical composition characterised by the fact that it contains synthetic lipoic acid; 95% ethyl alcohol; 1,2-propylene glycol, polyacrylic acid (any other hydrophilic gelling agent), triethanolamine, purified water; a method for preparing the local topical composition characterised by the fact that synthetic lipoic acid is dissolved while stirring in mixed ethyl alcohol and propylene glycol; at the same time polyacrylic acid is dispersed in a specified amount of water sufficient to reduce the ratio of the ingredients up to 100 wt %, after 3-hour swelling, the prepared solution is added to synthetic lipoic acid dissolved in mixed ethyl alcohol and propylene glycol and mixed up; the prepared composition is neutralised by a triethanolamine solution to pH 5.5-6.5 and mixed to form a light-yellow transparent gel-like mass. |
|
Method for preconception preparation in early recurrent miscarriage / 2519163 Invention refers to medicine, namely to obstetrics and gynaecology, and may be used for preconception preparation in early recurrent miscarriage caused by chronic genital inflammation or inflammatory hormonal ovarian insufficiency. That is ensured by 12 intravaginal introductions of disposable injectors with Dead sea mud gel as a therapeutic agent daily for 30 minutes within one therapeutic course upon completion of the anti-inflammatory treatment following the early miscarriage. |
|
Ointment containing encapsulated triterpenic acid or derivatives thereof / 2519133 Invention refers to a composition containing encapsulated triterpenic acid: betulinic acid, ursolic acid or derivatives thereof in the form of salts and esters, or triterpene alcohol - betulin, which may be used in medicine for treating and preventing viral infections caused by DNA and RNA-containing viruses, such as influenza viruses, oncogenic viruses, herpes virus, herpes zoster virus, as well as infections caused by gram-positive and gram-negative bacteria: Staphylococcus spp., Streptococcus spp., Enterococcus spp., Shigella spp., Escherichia spp., Salmonella spp., Proteus spp., Acinetobacter spp., Citrobacter spp., Pseudomonas spp., Serratia spp., Klebsiella spp., Antracoides spp., Cryptococcus spp., pathogenic fungi of the genus Microsporum, Trichophyton, Nocardia, Aspergillus, yeast-like fungi of the genus Candida, including multiresistant strains, as well as Actinomycetes and some pathogenic protozoa: Entamoeba histolytica, Trichomonas vaginalis. The invention presents the composition containing an active ingredient presented by 0.5 wt % of betulin or 0.5 wt % of encapsulated triterpenic acid: betulinic acid, ursolic acid or derivatives thereof in the form of salts and esters and others, and carriers presented by: β-cyclodextrins, fullerene, lecithins and polymers binding to the ingredients to form ingredient-carrier complexes, and excipients. |
|
Antibacterial composition, strain of bacteriophage escherichia coli, used for obtaining thereof / 2518303 Invention relates to field of food industry, biotechnology and deals with antibacterial composition and strain of bacteriophage Escherichia coli, used for obtaining said composition. Characterised composition includes filtrate of Escherichia coli phage lysate, obtained with application of strain of bacteriophage Escherichia coli, deposited in collection of museum of microorganisms of Federal Budget Institution of Science "State Research Centre for Applied Microbiology and Biotechnology" of the Federal Service on Customers' Rights Protection and Human Well-being Surveillance (FBIS SRC AMB of Rospotrebnadzor) under number Ph 64, filtrate of Escherichia coli phage lysate, containing coli bacteriophage, filtrate of staphylococcus phage lysate, filtrate of salmonella phage lysate, filtrate of Listeria monocyctogenes phage lysate and target additives in amount 1.0÷95.0 wt % of composition weight. |
|
Agent of peptide structure possessing anti-inflammatory, antibacterial, wound-healing, regenerative, analgesic, burntreating action and based dosage forms / 2517213 Group of inventions refers to pharmacology and medicine and concerns using a dipeptide of a general formula Tyr-Pro-X, where X - OH, NH2, OCH3, OC2H5, as an anti-inflammatory, antibacterial, wound-healing, regenerative, analgesic and burntreating agent for external application, as well as a dosage form for external application containing this dipeptide. |
|
Water-soluble bactericidal composition / 2517063 Composition contains the bactericidal substance Poviargol in the amount of 2.1-7.0 wt % and zosterin in the amount of 1.1-7.0 wt %. |
|
Method of treatment of animals with surgical sepsis / 2517053 Kobaktan is administered intramuscularly at a dose of 2 ml per 50 kg of body weight daily for 7 days, glutoxim is administered subcutaneously at a dose of 3 mg per 1 kg of body weight once in 2 days in an amount of 10 injections, and also 1-3 sessions of hemosorption is carried out with the interval of 24-48 hours. |
|
Purification and application of factor, contributing to wound healing / 2520817 Group of inventions relates to the field of biotechnology. Claimed is a method of purification of a factor, contributing to wound healing, which represents a hepatocyte growth factor (HGF). All stages of purification are carried out in the presence of antithrombin III (AT-III). In accordance with the claimed method carried out are: defrosting of the frozen HGF-containing source and removal of sediment from the defrosted source. After that, the obtained solution, which contains a supernatant and AT-III, is brought in contact with a carrier for affinity chromatography on an immobilised heparin. Then, the solution is separated from the carrier for affinity chromatography. The carrier is brought in contact with a desorption buffer with ionic strength sufficient for HGF desorption. The desorption buffer, containing HGF, AT-III and histidine-rich glycoprotein (HRGP) is collected. Also claimed are wound-healing compositions, which contain HGF, AT-III and/or HRGP, purified by the claimed method. |
|
Pharmaceutical compositions for dehydration, atrophy and removal of abnormal tissues / 2520754 Invention refers to the pharmaceutical industry, particularly to a pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues, and to using it. The pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues contains a composite of an inorganic polymer iron salt as an active ingredient; the composite of the inorganic polymer iron salt is polymer ferrous sulphate silicate (PFSS), or polyferrous silicate chloride (PFSC), or polyphosphate ferrous sulphate (PPFS). Using the pharmaceutical composition consists in preparing the drug for dehydration, atrophy and removal of abnormal tissues. |
|
Method of treating superficial thermal burns / 2519102 Affected areas of skin are coated with dressings impregnated with therapeutic preparations containing 1.0-2.0% hypromellose, an antiseptic specified in a group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron and 2% lidocaine hydrochloride. At the stage of wound exudation on the second or third post-injury day, the dressings impregnated with 2.0% hypromellose, the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron, and 2% lidocaine hydrochloride are used and changed once a day. At the stage of proliferation, the dressings impregnated with 1.0% hypromellose and the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron are used and changed every 2 days. At the stage of epithelisation, the dressings impregnated with 1.0% hypromellose and the antiseptic specified in the group: 4% boric acid, 0.05% chlorhexidine, 1% iodopyron are used and changed every 3 days until the wound surface is completely epithelised. |
|
Pharmacological composition / 2519090 Pharmacological composition for preparing drug forms in form of powder, solution or bandage consists of biocompatible film-generating polymer polyvinylpyrrolidone (Mm 20000), iodine and Novocain, taken in quantities, given in the invention formula. Pharmaceutical composition is intended for processing wound surface and treatment of burns. Composition possesses antiseptic, local anesthetic and wound-healing action. |
 Prolyl hydroxylase inhibitors / 2518071Invention relates to compound of formula |
|
Combination of lycopene, polyphenol and vitamins for care of keratin materials / 2517132 Invention relates to the field of cosmetology, namely to a cosmetic composition for peroral introduction, which contains a combination of lycopene, vitamin C, vitamin E and at least one polyphenol compound, obtained from pine bark, in which the ratio of weight content of polyphenol compound to the sum of weight contents of lycopene, vitamin C and vitamin E constitutes from 0.3 to 0.7, as s single active ingredient. |
|
Wound-healing drug / 2517065 Invention relates to a wound-healing drug which consists of stearic acid; castor oil; zinc stearate; 70% alcohol extract of a plant collection including oak tree bark, marigold flowers, wild chamomile flowers, nettle leaves, taken in ratio of 1:3:2:1, respectively; Na salts of fatty acids of wool fat; boric acid; vaseline; glycerine; triethanolamine; treated water; vegetable oil; Tipton weed extract; wild rose oil or sea buckthorn oil; 10% propolis oily solution; natural L-amino acid-peptide biocomplex obtained by extracting native paunch manure of ruminants with 2.0-3.0% NaCl solution; purified lanolin and derivatives thereof. |
|
Water-soluble bactericidal composition / 2517063 Composition contains the bactericidal substance Poviargol in the amount of 2.1-7.0 wt % and zosterin in the amount of 1.1-7.0 wt %. |
 Agent for burn and wound healing / 2513186Invention refers to using ultradisperse silver-containing systems as anti-inflammatory, anti-exudative and wound-healing agents. The ultradisperse silver-containing systems represent zero-valent silver metal nanocomposites at particle size 10-25 nm stabilised with arabinogalactine and its sulphated derivative. The invention also refers to an agent for wound and burn healing having anti-inflammatory, anti-exudative, wound-healing and antimicrobial activity, comprising said silver nanocomposites as a pharmacologically active substance and additionally containing carbomer, triethanolamine, glycerol or 1,2-propylene glycol and water. The agent is presented in the form of topical hydrophilic gel. The invention also refers to using the above agent for wound and burn healing in an individual in need thereof. |
|
Topical preparation for contaminated wound healing / 2512824 Present invention refers to a topical preparation for contaminated wound healing. The above preparation contains lidocaine hydrochloride 0.1-0.2%, thrombolysin 30-36%, metronidazole 0.25-0.5%, clindamycin 0.3-0.45%, rifampicine 0.45-0.6%, olive oil 10%, sea buckthorn oil 1.5-2.0%, starch 5.1% and silver water. |
|
Pharmaceutical composition for preventing and treating vascular disorders and neuropathies / 2521199 Pharmaceutical composition contains a combination of dalargin in an amount of 0.1-4 mg and vitamin specified in B1 (thiamine hydrochloride or thiamine bromide) or vitamin B6 (pyridoxine hydrochloride) or a mixture thereof in an amount of 25-100 mg. |
FIELD: chemistry.
SUBSTANCE: composition includes a bactericidal substance - catapol - in amount of 2.1-2.5 wt %, zosterin in amount of 1.1-5.0 wt % and distilled water.
EFFECT: providing a composition which stimulates a reparative process in external protective tissue, having anti-inflammatory and radioprotective action.
1 tbl, 1 ex
The invention relates to medicine, veterinary medicine, namely to the field result they have proved, dermatology, surgery, and is used for treatment and prevention of diseases and complications in humans and animals.
It is known the use of compositions as wound healing, dermatological products containing antiseptics, stimulators of tissue metabolism.
Known composition to stimulate repair of the skin (wounds), containing (wt.%): collagen farm animals 0,2-1,5; sulfated glycosaminoglycans of 0.002 to 0.05; water-soluble derivatives of cellulose of 0.05-2.5; water - the rest [EN 2092156, A61K 9/08, A61K 35/32; 10.10.1997].
A significant drawback of analogue is that the composition may cause allergic reactions because it is composed of the protein collagen.
The closest vehicle to the present invention is antiseptic [EN 1517173, A61K 31/14, 30.04.1997], which relates to antimicrobial compositions, contains the antiseptic katapola, sodium chloride, and water in specific proportions. The General features of the proposed and known means is used in both cases katapola as a bactericidal substance.
The disadvantages of the prototype: in the presence of antimicrobial activity of the drug has a mild reparative properties that can the t adversely affect the healing time of wounds and restoring the active life of the individual.
The technical task and the positive result of the invention is to provide a multifunctional tool to accelerate the healing of lesions of epithelial tissue and superficial wounds in all stages of the healing process of wounds, particularly burns of various etiologies, including radiation, as the most severe lesions of the skin, combined lesions. The inventive composition has the following distinctive features in the application: reduced duration of the latent period, the acceleration of the completion of the inflammatory period, early deadlines and shortening of the period of the formation of the epithelium, decrease or absence of period suppurative inflammation and lack of toxicity and allergenicity.
The problem is solved by obtaining a composition containing the following ingredients: as biologically active substances with reparative activity component related to the pectins obtained from marine plants of the family "Smolnikova" (Zosteraceae) - Zosterin (trade names: Zosterin, Zosterin ultra 30, Zosterin ultra 60, isosteric); katapola - antiseptic broad-spectrum (exhibits bactericidal activity against staphylococci, streptococci, gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa, Proteus, Klebsiella and others), has also protiveris the TV and virucidal activity (inactivates virus Herpes simplex); distilled water - up to 100 in the following mass ratios, wt%:
| Zosterin | 1,0-5,0 |
| The katapola | 0,1-5,0 |
| distilled water | rest |
The composition of the claimed composition was confirmed by standard methods.
An example of obtaining this composition.
To 94 g of distilled water, heated to 70°C, add 1 g of powder Zosterin and dissolved under stirring for 1.5-2 hours. After cooling to room temperature, to the resulting solution add 5 ml of 10% solution of the drug katapola and stirred for 1 hour to complete matching of components.
The effectiveness of the claimed compositions were evaluated in the experiments, put on white rats-males weighing 200-240 g model treatment of radiation injury III-a degree. For studies used healthy animals with clean skin, past the quarantine for 14 days. 1 day before the experiment at the proposed site of the skin of the back of the animals was removed hair with warm 15% solution of sodium sulphide, if necessary used method of hair removal skin of the animal.
Before irradiation of the skin of the animal is fixed in a horizontal position on a specially designed jig.
Radiation damage to the skin was modeled irradiation area nepilirovanny back skin of rats from a source of soft x-ray radiation to the installation PART 17 when the voltage on the tube 180 kV, anode current of 15 mA, the filter 1 mm Cu+1 mm A1, dose rate 52 R/min, skin-focal length 10 cm radiation Dose to the skin was 58 G, field exposure of 1.7×1.7 cm2. The body of the animal during irradiation of the skin was protected with lead plates with a thickness of 2 mm All investigated solutions was applied immediately after irradiation of the skin and continued to apply once daily (in the morning) during the whole period of healing beam ulcers until epithelialization of the skin to the detachment of the crust and restore the skin. As shown by experimental studies, all studied compounds were non-toxic, had no local irritating effect and was well tolerated by the animals with long-term local application.
Estimated visual indications of the formation of radiation damage to the skin: the appearance and severity of signs of inflammation at the site of exposure skin hyperemia (redness), scaling, swelling, duration of the inflammatory period and the formation of focus of radiation skin lesions (ulcers, covered with a dry crust). Reparative processes (healing local radiation injury) estimated p is the period of wound healing (terms detachment of crusts), the duration and intensity of wound healing. The intensity of wound healing was assessed by the index of wound healing, as defined by generally accepted metric - speed the healing of wounds.
Comparative data on the effectiveness of treatment of radiation injuries of the skin of animals (rats) solutions Kosterina, katapola and their compositions are given in the table below:
/tr>| Table | ||||||
| Experience ing group- p |
The composition of the solution | Signs of radiation injury to the skin (day) | Signs of healing of radiation damage to the skin (day) | The average speed they healed- ing ulcers (% per day) |
||
| The timing of the emergence of Patras- in |
Continue length inflammatory- tion of period |
Terms formed the formation of crust (ulcers) |
Time they healed- of ulcers |
Length the activities they healed- of ulcers |
||
| 1 | 1,0% | 7.7±0.7 | 4.8±0.5 | 12.7±2 | 28.3±2.4 | 15.8±2.6 | 6.8±1.0 |
| Zosterin | ||||||
| 2 | 0,5% | 7.5±02 | 4.0±0.5 | 12.0±0.4 | 29.0±0.8 | 16.0±1.2 | 6.4±0.5 |
| the katapola | ||||||
| 3 | 0,5% | 5.8±0.4 | 4.2±0.3 | 10.5±02 | 25.2±1.1 | 15.0±1.4 | 6.8±0.6 |
| the katapola | the | |||||
| +1,0% | ||||||
| Zosterin | ||||||
| 4 | 0,1% | Without treatment | ||||
| the katapola | ||||||
| +5,0% | ||||||
| Zosterin | ||||||
| 5 | 5,0% the katapola +1,0% Zosterin |
Without treatment | ||||
| 6 | 2,5% | 6.3±0.4 | 2.5±0.2 | 8.3±0.3 | 28.0±2.3 | 20.4±2.5 | 5.3±0.7 |
| Zosterin | ||||||
| Control | 9.3±0.8 | 4.7±0.8 | 14.7±0.8 | 33.0±2.9 | 17.5±2.6 | 6.1±0.9 |
Thus, the positive effect of the proposed solutions is that created polyfunctional composition, stimulating the reparative process in epithelial tissues of mammals that have anti-inflammatory, radioprotectors, antimicrobial activity, decreasing the degree of burn injury intended for external application in the form of skin application.
Literature
1. Afinogenov G., Panarin E.F. Antimicrobial polymers, SPb.: Hippocrates, 1993, 261 S.
2. Goncharenko E.N., Kudryashov SHE Radioprotective means of natural origin. The successes of modern biology. 1991, Vol.3, issue 2, s-316.
3. Saksonov P.P., B.C. Hamilton, Sergeev PV Radiation pharmacology. M.: Medicine, 1976, s-217.
4. Kolenchenko E.A., Sonin, L.N., Khotimchenko US Comparative evaluation of antioxidant activity of disketer fitiavana pectins from sea grass zostera marina and drugs antioxidants in vitro. Marine biology, 2005, T. 31, No. 5, s-383.
5. Zaporozhets T.S. Comparative immunological activity polyglycerol of marine origin. Antibiotics and chemotherapy, 2001, T. 46, No. 7, S. 6-10.
5. Vasin MV prophylaxis and treatment of radiation injuries. 2nd ed., supplementary, M, 2001,312 C.
Water-soluble bactericidal reparative composition comprising a bactericidal substance katapola, characterized in that it additionally contains polysaccharide Zosterin in the following ratio, wt.%:
| Zosterin | 1,1-5,0 |
| The katapola | 2,1-2,5 |
| Distilled water | rest |